Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.5% in the afternoon session after the stock ...

Moderna ($MRNA) stock jumped 17% on Thursday, fueled by speculation of potential buyout talks amid concerns over declining ...

Discover whether Moderna or BioNTech offers better long-term investment potential as both pivot from COVID-19 to innovative ...

Arcturus Therapeutics (ARCT) stock falls as Citi downgrades the company following weak mid-stage trial data for its cystic ...

The biotech's innovative qualities will come in handy. Long gone are the days when Moderna ( MRNA 2.66%) would generate over $18 billion in annual sales from its COVID-19 vaccine. Over the past couple ...

With the three healthcare stocks featured below, any "buying the dip" in them today could prove to be a regretful mistake in ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Durban-headquartered pharmaceutical major Aspen Pharmacare confirmed in a Sens announcement on Friday that it has reached a ...

Major stock indexes rose Thursday, as investors digested the latest batch of corporate earnings and China trade news.